摘要
本文用金黄色葡萄球菌（Staphylococcusaureus）、乙型溶血性链球菌（StreP－tococcushemolyticus）、卡介苗（BCG）、伤杆菌（Salmonellatyphi）等多种细菌抗原免疫SD大鼠，并从其脾脏、胸腺等淋巴组织通过透析的方法获得透析外液，再加上构才己等中药透析的小分子（MW≤10KD）物质，制备成混合制剂（癌得清）。然后以DBA／2小鼠荷L5178Y、P815肿瘤为模型，分别在肿瘤细胞接种后及接种前后腹腔注射上述制剂，观察其抑瘤作用和荷瘤小鼠脾细胞NK、LAK活性及产生IL－2活性的影响。结果表明，该制剂可明显抑制L5178Y、P815肿瘤生长并能显著增强荷瘤小鼠脾脏NK、LAK活性，增强脾细胞产生IL－2的能力。
Many kinds of antigen (Staph aureus, S hemolyticus, BCG, et al) immunized SDrats. Dialysate was obtained from spleen and thymus of SD rats by dialysising, andadding low molecular weight(MW≤10KD) dialysate from Lycium chineses etc ChineseMedicine. This preparation is named Ederpinil. Then, L5178Y P815 tumors bearingDBA mice were used as modeals Respectively, after of inoculation of tumors, before andafter of inoculation of tumors, Ederqini were adrninistrated i. p. Then the action of antitumor and protect - treat tumor, the NK, LAK, IL - 2 activity tv the 15178Ytumorbaering mice were assaied. The results suggested Ederqini ingection can inhibted thegrowth of L5178Y, P815 and can enhance the IL- 2 activity and NK, LAK activitydistinctly.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1998年第4期281-283,共3页
Cancer Research on Prevention and Treatment
关键词
生物应答调节剂
癌得清注射液
抗癌药
Biological response modifier
Ederqini ingection
Tumor treatment
